What happened Vivos Therapeutics, Inc. (Nasdaq: VVOS) said Nasdaq's Listing Qualifications staff told it on October 20, 2026, that it now complies with Rule 5550(b)(1). The rule requires stockholders' equity of at least $2.5 million. The notice came after Vivos closed an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided […]